Tower Research Capital LLC recently announced the acquisition of new stake in Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA). The institutional investor has increased its shareholding in the Healthcare company by 11.16% to 9533.0 shares with purchase of 957.0 shares. This fresh investment now brings its stake to 0.07% valued currently at $1678.0.
With over 13.61 million Sonoma Pharmaceuticals Inc. (SNOA) shares trading Tuesday and a closing price of $0.18 on the day, the dollar volume was approximately $2.45 million. The shares have shown a negative half year performance of -82.96% and its price on 01/09/24 gained nearly 2.74%. Currently, there are 13.68M common shares owned by the public and among those 13.46M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 200,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Sonoma Pharmaceuticals Inc. are Fidelity Extended Market Index Fu, Fidelity Nasdaq Composite Index F, and Vanguard Extended Market Index Fu. Fidelity Extended Market Index Fu owns 29083.0 shares of the company’s stock, all valued at over $5119.0. Vanguard Extended Market Index Fu now owns shares totaling to 0.03% of the shares outstanding.
However, the script later moved the day high at 0.2263, up 2.74%. The company’s stock has a 5-day price change of 1.10% and -75.47% over the past three months. SNOA shares are trading 2.00% year to date (YTD), with the 12-month market performance down to -83.86% lower. It has a 12-month low price of $0.12 and touched a high of $2.68 over the same period. SNOA has an average intraday trading volume of 1.06 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.38%, 6.01%, and -76.02% respectively.
Institutional ownership of Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) shares accounts for 0.92% of the company’s 13.68M shares outstanding. Mutual fund holders own 0.63%, while other institutional holders and individual stakeholders account for 1.69% and 0.29% respectively.
It has a market capitalization of $2.52M and a beta (3y monthly) value of 1.34. The earnings-per-share (ttm) stands at -$1.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.22% over the week and 15.27% over the month.
Analysts forecast that Sonoma Pharmaceuticals Inc. (SNOA) will achieve an EPS of -$0.21 for the current quarter, -$0.17 for the next quarter and -$0.45 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.21 while analysts give the company a high EPS estimate of -$0.21.
